Literature DB >> 2867105

Thyroid-stimulating autoantibodies usually contain only lambda-light chains: evidence for the "forbidden clone" theory.

J Knight, P Laing, A Knight, D Adams, N Ling.   

Abstract

Burnet's "forbidden clone" theory would predict that in patients with Graves' disease the pathogenic thyroid-stimulating autoantibody (TSab)-secreting clones arise by somatic mutation. Because each lymphocyte and its progeny are permanently committed to producing antibodies of a single light chain type, a clone arising by somatic mutation occurring in a single cell would be expected to produce autoantibodies of exclusively kappa or exclusively lambda type in an individual patient. Using affinity chromatographic techniques and monoclonal antibodies, we investigated the light chain type of TSab in 11 patients with Graves' disease. In all patients tested, TSab activity was confined to a single light chain type, confirming the recent work of Zakarija who used affinity chromatography with polyclonal antisera, but contrasting with earlier studies which used immuno-precipitation methods. Furthermore, the light chain type was lambda in 10 of the 11 patients. These observations provide support for the forbidden clone theory. In addition, the marked preponderance of patients producing TSab of the lambda-light chain type indicates that TSab are more likely to arise from the lambda repertoire of clones than from the kappa repertoire and suggests that immunoglobulin light chain V genes may be genetic determinants for susceptibility to Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2867105     DOI: 10.1210/jcem-62-2-342

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  11 in total

1.  Autoantibodies to type VII collagen have heterogeneous subclass and light chain compositions and their complement-activating capacities do not correlate with the inflammatory clinical phenotype.

Authors:  K Gandhi; M Chen; S Aasi; J C Lapiere; D T Woodley; L S Chan
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Immunological studies in the hyper-immunoglobulin D syndrome.

Authors:  A Haraldsson; C M Weemaes; A W De Boer; J A Bakkeren; G B Stoelinga
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

3.  Kappa/lambda immunoglobulin distribution in Graves' thyroid-stimulating antibodies. Simultaneous analysis of C lambda gene polymorphisms.

Authors:  R C Williams; N J Marshall; K Kilpatrick; J Montano; P M Brickell; M Goodall; P A Ealey; B Shine; A P Weetman; R K Craig
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

Review 4.  Immunity to the thyroid-stimulating hormone receptor.

Authors:  J Furmaniak; B R Smith
Journal:  Springer Semin Immunopathol       Date:  1993

5.  Thyroid-stimulating antibody activity between different immunoglobulin G subclasses.

Authors:  A P Weetman; M E Yateman; P A Ealey; C M Black; C B Reimer; R C Williams; B Shine; N J Marshall
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

6.  Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor.

Authors:  Gregorio D Chazenbalk; Pavel Pichurin; Chun-Rong Chen; Francesco Latrofa; Alan P Johnstone; Sandra M McLachlan; Basil Rapoport
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

7.  Physical location of the human immunoglobulin lambda-like genes, 14.1, 16.1, and 16.2.

Authors:  T R Bauer; H E McDermid; M L Budarf; M L Van Keuren; B B Blomberg
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

8.  Altered immunoglobulin concentrations and light chain ratios in juvenile onset mixed connective tissue disease.

Authors:  A Haraldsson; H A Tiddens; T Fiselier; J A Bakkeren; C M Weemaes
Journal:  Clin Rheumatol       Date:  1995-01       Impact factor: 2.980

9.  Immunoglobulin G, A, and M light chain ratios in some humoral immunological disorders.

Authors:  A Haraldsson; M Jaminon; J A Bakkeren; G B Stoelinga; C M Weemaes
Journal:  Scand J Immunol       Date:  1992-07       Impact factor: 3.487

10.  The autoimmune model of schizophrenia.

Authors:  D D Adams; J G Knight; A Ebringer
Journal:  ISRN Psychiatry       Date:  2012-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.